IS8096A - Notkun karbamasepínafleiða til að meðhöndla órósemi í sjúklingum er þjást af vitglöpum - Google Patents

Notkun karbamasepínafleiða til að meðhöndla órósemi í sjúklingum er þjást af vitglöpum

Info

Publication number
IS8096A
IS8096A IS8096A IS8096A IS8096A IS 8096 A IS8096 A IS 8096A IS 8096 A IS8096 A IS 8096A IS 8096 A IS8096 A IS 8096A IS 8096 A IS8096 A IS 8096A
Authority
IS
Iceland
Prior art keywords
agitation
compound
treat patient
formula
combination
Prior art date
Application number
IS8096A
Other languages
English (en)
Inventor
Shua-Haim Joshua
Martenyi Ferenc
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IS8096A publication Critical patent/IS8096A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS8096A 2003-04-01 2005-10-27 Notkun karbamasepínafleiða til að meðhöndla órósemi í sjúklingum er þjást af vitglöpum IS8096A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45933803P 2003-04-01 2003-04-01
PCT/EP2004/003418 WO2004087166A1 (en) 2003-04-01 2004-03-31 Use of carbamazepine derivatives for the treatment of agitation in dementia patients

Publications (1)

Publication Number Publication Date
IS8096A true IS8096A (is) 2005-10-27

Family

ID=33131880

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8096A IS8096A (is) 2003-04-01 2005-10-27 Notkun karbamasepínafleiða til að meðhöndla órósemi í sjúklingum er þjást af vitglöpum

Country Status (25)

Country Link
US (2) US20070066593A1 (is)
EP (1) EP1613328B8 (is)
JP (1) JP2006522050A (is)
KR (1) KR20050121236A (is)
CN (1) CN1767833A (is)
AT (1) ATE425756T1 (is)
AU (1) AU2004226805B2 (is)
BR (1) BRPI0408956A (is)
CA (1) CA2521371A1 (is)
DE (1) DE602004020060D1 (is)
ES (1) ES2323270T3 (is)
HK (1) HK1090543A1 (is)
HR (1) HRP20050872A2 (is)
IS (1) IS8096A (is)
MA (1) MA27638A1 (is)
MX (1) MXPA05010608A (is)
NO (1) NO20054994L (is)
NZ (1) NZ542554A (is)
PL (1) PL1613328T3 (is)
PT (1) PT1613328E (is)
RU (1) RU2351338C2 (is)
TN (1) TNSN05247A1 (is)
TW (1) TW200501962A (is)
WO (1) WO2004087166A1 (is)
ZA (1) ZA200507439B (is)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0517740D0 (en) * 2005-08-31 2005-10-12 Novartis Ag Organic compounds
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EP2312945A4 (en) * 2008-08-13 2012-05-09 Merck Sharp & Dohme PURE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER
CN102180965B (zh) * 2011-03-02 2014-01-01 广州金域医学检验中心有限公司 卡马西平免疫原、抗卡马西平特异性抗体、检测试剂及检测试剂盒
CN102183659B (zh) * 2011-03-02 2014-07-02 广州金域医学检验中心有限公司 一种卡马西平检测方法
RU2504367C1 (ru) * 2012-06-05 2014-01-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Амурская государственная медицинская академия" Минздравсоцразвития Российской Федерации Способ коррекции психического состояния пациентов и антиоксидантного статуса при органическом расстройстве личности

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH500196A (de) * 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
US3637661A (en) * 1970-03-04 1972-01-25 Ciba Geigy Corp 10-hydroxy-10 11-dihydro-dibenzazepine derivative
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
PT101732B (pt) * 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
US5736647A (en) * 1995-08-07 1998-04-07 Oval Corporation Vortex flow meter detector and vortex flow meter
CN1367697A (zh) * 1998-10-16 2002-09-04 詹森药业有限公司 改善认识的疗法
AU2465401A (en) * 1999-12-30 2001-07-16 Proteotech, Inc. Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidoses
GB0113663D0 (en) * 2001-06-05 2001-07-25 Novartis Ag Use of organic compounds
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients

Also Published As

Publication number Publication date
DE602004020060D1 (de) 2009-04-30
US20070066593A1 (en) 2007-03-22
RU2351338C2 (ru) 2009-04-10
PL1613328T3 (pl) 2009-08-31
EP1613328B8 (en) 2009-06-10
TNSN05247A1 (en) 2007-06-11
NZ542554A (en) 2008-10-31
WO2004087166A1 (en) 2004-10-14
JP2006522050A (ja) 2006-09-28
HK1090543A1 (en) 2006-12-29
ES2323270T3 (es) 2009-07-10
ATE425756T1 (de) 2009-04-15
CN1767833A (zh) 2006-05-03
BRPI0408956A (pt) 2006-04-04
NO20054994L (no) 2005-10-26
MXPA05010608A (es) 2005-11-23
RU2005133478A (ru) 2007-06-10
HRP20050872A2 (en) 2006-12-31
AU2004226805A1 (en) 2004-10-14
US20090192142A1 (en) 2009-07-30
PT1613328E (pt) 2009-06-15
CA2521371A1 (en) 2004-10-14
TW200501962A (en) 2005-01-16
EP1613328B1 (en) 2009-03-18
MA27638A1 (fr) 2005-11-01
EP1613328A1 (en) 2006-01-11
KR20050121236A (ko) 2005-12-26
ZA200507439B (en) 2007-06-27
AU2004226805B2 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
IS8096A (is) Notkun karbamasepínafleiða til að meðhöndla órósemi í sjúklingum er þjást af vitglöpum
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
NO20073465L (no) Benzotiazol-derivater
BRPI0416212A (pt) derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7&#39;-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
ATE365742T1 (de) 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren
TR200102782T2 (tr) Bisiklik heterosikleler, bu bileşikleri ihtiva eden farmasötik kompozisyonlar
CY1106645T1 (el) Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος
ATE402176T1 (de) Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
ATE410426T1 (de) Heterocyclische verbindungen alsccr5-antagonisten
DE602004020685D1 (de) Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3-cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i-epsilon
NO20032261L (no) Medisinske preparater
ATE541567T1 (de) Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
TW200519101A (en) Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
EA200601687A1 (ru) Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1
BRPI0514380A (pt) amidas de ácido 5- e 6-amnoalquil indol-2-carboxìlico 3-substituìdo e análogos relacionados como inibidores de caseìna quinase i
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
ATE535242T1 (de) Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie
BR0314930A (pt) Derivados de pirazol e seu uso como agentes terapêuticos para doenças mediadas por hiv
NO20061966L (no) Bicyklo[3.1.1.]heptansubstituerte benzimidazolon- og kinazolinonderivater som agonister for humane ORL1 reseptorer
EA200900313A1 (ru) Производные бензо[1,2,3]тиадиазина
EA200500235A1 (ru) Новые производные пиперазинона для лечения нарушений, связанных с 5-ht-рецептором